Mast Cell Disease Research
Our charity works to connect patients to clinical trials and research studies on mast cell diseases for which they may be eligible and raises money to support research into mast cell diseases.
Patients with indolent systemic mastocytosis (ISM) or smouldering systemic mastocytosis (SSM) may be eligible for ongoing trials of a medication from Blueprint Medicines called Avapritinib (BLU-285). For more information from the company about the drug and the study, you may visit Blueprint Medicine.
The listing for this Phase 2 trial which compares the safety and efficacy of this experimental medicine against a placebo can be seen here: Clinical Register
Please contact us if you would like to learn more about these trials in the UK.
Deciphera Pharmaceuticals is running a Phase 1 trial to establish the proper dose and tolerability of DCC-2618 in patients with advanced forms of mastocytosis. For more information about the drug, you may visit Deciphera Pharmaceuticals. Please contact us if you would like to learn more about these trials in the UK.
A research group in the UK has a small study looking at people with serum tryptase levels over 20ng/ml to assess whether they have Hereditary Alpha Tryptasaemia. For more information please contact us.
When funds allow, we make grants to researchers for research on mast cells and mast cell diseases. Email us to learn more.